ASH 2022 Conference Coverage
J

ASH 2022 Phase III SUNMO Trial: Evaluating the Efficacy & Safety of Mosunetuzumab + Polatuzumab Vedotin vs. Rituximab + Gemcitabine & Oxaliplatin in R/R Aggressive B-Cell NHL

By ASH 2022 Conference Coverage FEATURING Jason Westin
By ASH 2022 Conference Coverage FEATURING Jason Westin
296 views
December 19, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
05:38
GRACE

Epcoritamab in NHL - Incidence and Management of CRS

Feat. T. Phillips
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
26:58
Total Health

Update on Cellular Therapy in Lymphoma

Feat. B. Randolph
33:11
Total Health

Bispecific Antibodies and CAR T-Cells for NHL: Challenges and Opport…

Feat. K. Komanduri
10:49
Monia Marchetti

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

42:09
University of Colorado Department of Medicine

Immunotherapy in Lymphomas: The Present and the Future

Feat. M. Kamdar
06:38
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Updated Results From EPCORE NHL-1 - Effec…

Feat. Y. Karimi
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
18:18
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Emerging BCL2 Inhibitors

Feat. M. Ann Anderson
17:36
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The Emergence of Bispecific Antibodies in Aggressive B-Ce…

Feat. M. Hutchings
11:12
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: Indolent B-Cell Lymphoma

Feat. L. Nastoupil
14:36
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

The Latest Data on New Therapies in FL and MZL

Feat. J. Carter
12:43
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Bispecific Antibodies or CAR T-Cells for Indolent B-NHL?

Feat. C. Jacobson
13:22
SOHO 2022 Tenth Annual Meeting

SOHO 2022: The Next Generation of Novel Agents in Development for Ag…

Feat. J. Westin
22:38
Indy Hematology Review

Immune Effector Cell Therapy for Lymphoid Malignancies: What to Do a…

Feat. T. Phillips
38:55
Indy Hematology Review

Managing Indolent and Mantle Cell Lymphomas With Targeted and Cellul…

Feat. G. Salles